Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 143 citing articles:

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Stergios A. Pοlyzos, Јannis Kountouras, Christos S. Mantzoros
Metabolism (2018) Vol. 92, pp. 82-97
Closed Access | Times Cited: 937
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 567
NAFLD as a continuum: from obesity to metabolic syndrome and diabetes
Amélio F. Godoy‐Matos, Wellington S. Silva Júnior, Cynthia Melissa Valério
Diabetology & Metabolic Syndrome (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 477
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Reenam S. Khan, Fernando Bril, Kenneth Cusi, et al.
Hepatology (2018) Vol. 70, Iss. 2, pp. 711-724
Open Access | Times Cited: 418
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 348
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
S. Kahl, Sofiya Gancheva, Klaus Straßburger, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 298-305
Open Access | Times Cited: 266
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 217
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 190
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes—2020

Diabetes Care (2019) Vol. 43, Iss. Supplement_1, pp. S37-S47
Open Access | Times Cited: 186
4. Comprehensive Medical Evaluation and Assessment of Comorbidities:Standards of Medical Care in Diabetes—2019

Diabetes Care (2018) Vol. 42, Iss. Supplement_1, pp. S34-S45
Open Access | Times Cited: 169
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean‐François Dufour, Cyrielle Caussy, Rohit Loomba
Gut (2020) Vol. 69, Iss. 10, pp. 1877-1884
Open Access | Times Cited: 168
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways
Olufunto O. Badmus, Sarah A. Hillhouse, Christopher D. Anderson, et al.
Clinical Science (2022) Vol. 136, Iss. 18, pp. 1347-1366
Open Access | Times Cited: 168
<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 161-174
Open Access | Times Cited: 137
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 31
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
André Scheen
Diabetes & Metabolism (2019) Vol. 45, Iss. 3, pp. 213-223
Closed Access | Times Cited: 123
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Gabriele Fragasso, Mark C. Petrie, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1495-1503
Open Access | Times Cited: 121
Metabolic Targets in Nonalcoholic Fatty Liver Disease
William P. Esler, Kendra K. Bence
Cellular and Molecular Gastroenterology and Hepatology (2019) Vol. 8, Iss. 2, pp. 247-267
Open Access | Times Cited: 120
Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
Adriana Marton, Tatsuroh Kaneko, Jean‐Paul Kovalik, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 1, pp. 65-77
Closed Access | Times Cited: 109
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
Hirokazu Takahashi, Takaomi Kessoku, Miwa Kawanaka, et al.
Hepatology Communications (2021) Vol. 6, Iss. 1, pp. 120-132
Open Access | Times Cited: 101
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 93
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Agostino Di Ciaula, Salvatore Passarella, Harshitha Shanmugam, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5375-5375
Open Access | Times Cited: 92
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review
Henith Raj, Harsh Durgia, Rajan Palui, et al.
World Journal of Diabetes (2019) Vol. 10, Iss. 2, pp. 114-132
Open Access | Times Cited: 80
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Kai‐Fan Tsai, Yung‐Lung Chen, Terry Ting-Yu Chiou, et al.
Antioxidants (2021) Vol. 10, Iss. 8, pp. 1166-1166
Open Access | Times Cited: 79
The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
Ziyu Meng, Xiaohuan Liu, Ting Li, et al.
International Immunopharmacology (2021) Vol. 94, pp. 107492-107492
Closed Access | Times Cited: 77
SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
Caroline Wei Shan Hoong, Marvin Wei Jie Chua
Endocrinology (2021) Vol. 162, Iss. 8
Open Access | Times Cited: 60
Page 1 - Next Page

Scroll to top